In this time of liability reform, pharma deserves the chance to align its economic interests with its ethical obligations to the patient.

Novartis to Expand Generics Hold

CBER Draft Guidance for Spore-Formers and Plasmid Vaccines

GlaxoSmithKline Rebrands AIDS Drugs

FDA Creates New Drug Safety Board

Drug Safety Top Issue for New FDA Commissioner Crawford

FDA Reopens Comment Period on Biological Products Development Workshop

FDA's $1.9 Billion Budget Proposal Banks on User Fee Revenues

Steer small.

The USP prepares for its quinquennial conference in March.

MHRA to Reinspect Chiron Flu Vaccine Plant

Committees make prudent decisions and avoid mistakes, but they're afraid of the new.

Pharmaceutical Science & Technology News

Pharmaceutical Science & Technology News

On the other hand, if we don't keep up the pressure on counterfeiting in the US, we may share the plight of the developing world, where nearly 25% of all drugs sold are fakes.

Amid the finger-pointing, hand-wringing, and bloviating, the supply of hard, technical information remains frustratingly small.

Pharmaceutical Science & Technology News

Pharmaceutical science and technology news

Pharmaceutical science and technology news

Pharmaceutical Science & Technology News

Beyond the inevitable debate over profit margins, the increasing range and effectiveness of modern medicine leave us with one core issue: the high price of success.

The authors dispel common misinterpretations of the United States Pharmacopeia.

Pharmaceutical Science & Technology News

Pharmaceutical Science & Technology News

Pharmaceutical Science & Technology News

Pharmaceutical Science & Technology News

A recent USP gathering generated creative suggestions for the March 2005 USP convocation.